tbuckley/cabot-search huggingface dataset:
Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab + irinotecan as predictive factor of efficacy and outcome
Authors: B. Vincenzi, D. Santini, C. Funaioli, C. Pinto, F. Di Fabio, S. Galluzzo, M. Silletta, F. Battistoni, G. Tonini
Journal: Journal of Clinical Oncology (2008)

4106 Background: Magnesium plays a role in a large number of cellular metabolic reactions. Cetuximab is able to induce hypomagnesaemia by interfering with magnesium (Mg2+) transport in the kidney. We designed this trial to investigate if Mg2+ serum levels modifications may be related with clinical response and outcome in advanced colorectal cancer (CRC) patients during treatment with cetuximab plus irinotecan (CTX+CPT11). Methods: 91 pretreated metastatic CRC patients were evaluated for Mg2+ serum levels. The following time-points were analyzed: before 1, 7, 14, 21, 50 and 92 days after the start of treatment. Results: basal Mg2+ median levels were significantly decreased just seven days after the first anticancer infusion and progressively decreased along all the time points, reaching the highest significance at the last time point (P<0.0001). 46 patients showed a reduction in median Mg2+ circulating levels of at least 20% within the third week after the first infusion respect to the basal time point. Patients with this reduction showed a response rate of 68.0% vs 29.5% in the non reduced Mg2+ group. The median time to progression (TTP) was 6.7 vs 3.9 months in the reduced Mg2+ group and in that without, respectively (p<0.0001). Overall survival (OS) was longer in patients with Mg2 reduction than in those without (10.5 vs 7.5 months, p=0.02). Conclusions: our results confirm that cetuximab treatment may induce a reduction of Mg2+ circulating levels and offer the first evidence that early Mg2+ reduction may represents a new predictive factor of efficacy in heavily pretreated advanced CCR patients treated with CTX+CPT11. No significant financial relationships to disclose.
Immune Regulatory Properties Are a Common Feature Of Stem Cells
Authors: Mariano Di Trapani, Giulio Bassi, Mario Ricciardi, Emanuela Fontana, Francesco Bifari, Luciano Pacelli, Luca Giacomello, Michela Pozzobon, Francois Feron, Paolo De Coppi, Piero Anversa, Guido Fumagalli, Ilaria Decimo, Cedric Menard, Karin Tarte, Mauro Krampera
Journal: Blood (2013)
&lt;italic&gt;Brief Communication:&lt;/italic&gt; Development of Hepatocellular Carcinomas in Rats Treated With Benzene Hexachloride&lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;
Authors: N. Ito, H. Nagasaki, S. Sugihara, Y. Miyata, M. Arai, T. Shirai
Journal: JNCI Journal of the National Cancer Institute (1975)

The effects of prolonged oral administration of the α-, β-, γ-, and δ-isomers of benzene hexachloride (BHC) on rat liver were examined histologically. Welldifferentiated hepatocellular carcinomas were observed in the liver of rats fed a basal diet containing 1,500 or 1,000 parts per million (ppm) of α-BHC for 72 weeks. Many typical nodular hyperplasias developed in all groups given 1,500 or 1,000 ppm α-BHC. In non-neoplastic areas, slight oval cell infiltration and bile duct proliferation were seen. No neoplastic changes or other abnormal findings, such as oval cell infiltration, fatty changes, fibrosis, or bile duct proliferation of the liver, were observed in groups receiving 500 ppm α-, β-, γ-, or δ-BHC.
Presurgical Serum Immunoglobulin Concentrations and the Prognosis of Operable Breast Cancer in Women&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN2"&gt;3&lt;/xref&gt;
Authors: D R Ownby, H E Ownby, J Bailey, J Frederick, B Tilley, S C Brooks, J Russo, G Heppner, M Brennan
Journal: JNCI Journal of the National Cancer Institute (1985)

Serum concentrations of IgG, IgA, IgM, IgE, and allergen-specific IgE were measured in presurgical serum samples from 400 women admitted to a multidisciplinary study of primary breast cancer. The relationships between the serum immunoglobulins and patient survival were analyzed with the use of a Cox proportional hazards linear model. After adjustment for TNM stage, tumor histopathologic grade, and estrogen receptor (E2R) status, lower IgM concentrations were associated with longer survival. Lower IgE concentrations were also associated with longer survival, but only in patients whose tumors were E2R positive. IgG and IgA were not related to survival. Serum IgM and IgE concentrations, allergen-specific IgE scores, and the tumor E2R status were combined to construct a three-level risk classification that was more prognostic than any of the individual components. Cox model analysis demonstrated that this combination of immunologic and hormonal variables provided significant new information beyond that obtained from TNM staging and histopathologic grading of the tumors (P = .01). This new information may be useful to physicians in advising patients with primary, operable breast cancer about the relative risks and benefits of adjuvant therapy and in designing clinical trials of adjuvant therapy.
Galactorrhea Subsequent to Contraceptive Hormones
Journal: New England Journal of Medicine (1966)

To the Editor: The recent Brief Recording of Gregg entitled Galactorrhea after contraceptive hormones. which appeared in the June 23 issue of the Journal has prompted the report of the following case.  A 28-year-old woman has been followed after the onset galactorrhea within the initial month after cessation of orally ingested contraceptives consisting of norethynodrel with mestranol (Enovid) for 9 months followed by norethindrone with  mestranol (Ortho-Novum) for 17 months.  Amenorrhea was present for the initial 2 months followed by 2 menstrual periods and subsequent amenorrhea to this date (3 months).  Physical findings were unremarkable except for the easily demonstrable breast discharge.  Laboratory studies included normal protein bound iodine and uptake of radioactive iodine electroencephalogram and skull fils.  Gonadotropins were positive on 2 occasions at 16 mouse units.  In view of the known hypothalamic site of action of progestational agents and similiar patterns with other drugs producing galactorrhea the disorder was attributed to hypothalamic dysfunction that is release of inhibition of prolaction.(FULL TEXT)
Triple-negative breast cancer tumors in Peruvian patients: Worst prognostic to reach surgery after standard neoadjuvant chemotherapy.
Authors: T. Vidaurre, S. M. Quintana Truyenque, R. Mantilla, M. León, F. Doimi, C. E. Vigil, E. C. Alegría, L. Mas, F. Suazo, H. L. Gómez
Journal: Journal of Clinical Oncology (2010)

e11020 Background: Triple-negative breast cancer is an aggressive disease with poor clinical outcomes. This breast cancer subtype is negative for ER/PR receptors and HER2 protein and is managed with standard chemotherapy (CT) as anthracycline and/or taxane-based CT. The study aim is to evaluate the probability of surgery resectability after neoadjuvant CT in triple-negative vs. non-triple-negative breast cancer tumors. Methods: 116 II-III stage breast cancer pts were included in a randomized study for FAC vs. paclitaxel/FAC as a neoadjuvant CT at INEN - Perú. CT was 6 FAC cycles vs. 12 week paclitaxel followed by 4 FAC cycles. Clinical evaluations were performed at every visit. Results: 116 pts registered and 110 pts eligible and analyzable, 54 to FAC and 56 to paclitaxel/FAC. Treatment groups were balanced for age, ER, PR, HER2 and baseline tumor size. Most of the patients were III-B stage in both groups. Mean age in years by FAC 48.7 and by paclitaxel/FAC 49.9. Mean baseline tumor size in cm. by FAC 9.62 and by paclitaxel/FAC 9.10. Univariate analysis show 41 (52.6%) pts with FAC have reached surgery vs. 37 (47.4%) with paclitaxel/FAC (p = 0.48). In both treatment groups by IHC markers, pts have reached surgery were 26 (33.3%) ER negative vs. 52 (66.7%) ER positive (p < 0.05), 38 (48.7%) PR negative vs. 40 (51.3%) PR positive (p < 0.05) and 65 (83.3%) HER2 negative vs. 13 (16.7 %) HER2 positive (p = 0.55). Multivariate analysis shows the probability of reaching surgery with paclitaxel/FAC trend to be lower than FAC (OR = 0.76 – 95%CI: 0.29 -1.95). In both treatment groups by IHC markers, ER positive have 4 times more chances to reach surgery than ER negative (OR = 4.36 – 95%CI: 1.04–18.33), PR positive and HER2-positive trends to have more chances to reach surgery than ER negative and HER2 negative, but are not significant. Finally, the probability of reaching surgery with standard neoadjuvant CT (FAC and paclitaxel/FAC) is 6 times more in breast cancer tumors non-triple-negative vs. triple-negative (OR = 6.36 – 95%CI: 2.48–16.33). Conclusions: Triple-negative breast cancer tumors seem to not reach surgery resectability vs non-triple-negative tumors after standard neoadjuvant CT anthracycline or anthracycline/taxane-based CT. No significant financial relationships to disclose.
A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors
Authors: E. K. Rowinsky, S. Pacey, A. Patnaik, A. O'Donnell, M. M. Mita, P. Atadja, B. Peng, M. Dugan, J. W. Scott, J. S. De Bono
Journal: Journal of Clinical Oncology (2004)

3022 Background: LAQ824 is a novel cinnamic acid hydroxamate that inhibits HDAC activity and acetylates hsp90 thereby inducing proteosomal degradation of Bcr-Abl and her-2. Methods: LAQ824 was administered as a 3 hr IV infusion on days 1–3 of a 21 day cycle to adult pts with advanced solid tumors. A modified continuous reassessment method (MCRM) was used. Results: 28 pts (median age: 54 yrs; 16M, 12F) were treated at 7 dose levels (mg/m2): 6 (3 pts); 12 (4 pts); 24 (4 pts); 36 (4 pts); 48 (4 pts); 72 (8 pts); 100 (1 pt.). WHO PS: 0 (7 pts.), 1 (19 pts.), 2 (2 pts.). Grade 3 (G3) or G4 toxicities included transient G3 transaminitis (2 pts), G3 fatigue (1 Pt), G3 atrial fibrillation, without changes in QTc (1 pt), G3 creatinine increase, in 1 pt with advanced prostate cancer, and grade 4 ↑ bilirubin in 1 pt with liver metastases. Other toxicities: transient (<1 wk) G2 transaminitis (3 pts); G2 hyperbilirubinemia (1 pt); transient (< 1 wk) G3 thrombocytopenia (3 pts); G2 fatigue (3 pts) and G2 nausea (5 pts). Six of 7 pts with LFT abnormalities had liver metastases. Monitoring with > 400 ECGs on study, demonstrated 1 ECG with a QTc > 500 msec. 3/28 pts had stable disease: 5 (SCLC), 6 (melanoma), and 10 (hepatoma) cycles. PD assessment for histone acetylation (HA) in peripheral blood lymphocytes demonstrated increases at ≥ 12 mg/m2, increases on days of dosing at ≥ 36 mg/m2, increases for at least 24 hours post dose at ≥ 48 mg/m2, and increases for at least 48 hours post dose at ≥ 72 mg/m2. PK was evaluated in 25 pts (over 6–72 mg/m2) by noncompartmental analysis. Plasma LAQ824 concentrations were determined by HPLC/MS/MS assay. Exposure (AUC) increased proportionally with increasing dose. Mean AUCs(0–24) were 240.6 and 2721.7 ng.h/mL, respectively, for 6 and 72 mg/m2 on Day 1. Mean terminal half-lives ranged from 8 to 14 hr. Comparison of AUC on Day 1 and 3 indicated a 1.5 fold drug accumulation. Cmax was observed at 1.5 h after the beginning of infusion in > 50% of patients, indicating non-linear PK. Conclusions: LAQ824 is a novel HDAC inhibitor which is well tolerated and exhibits dose dependent PD effects. Evaluation of pts at 72 mg/m2dose level is in progress. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Pharmaceutics Novartis Novartis Novartis
Antimalarial Activity of 77 Phospholipid Polar Head Analogs: Close Correlation Between Inhibition of Phospholipid Metabolism and In Vitro Plasmodium Falciparum Growth
Authors: Marie L. Ancelin, Michèle Calas, Jacques Bompart, Gérard Cordina, Dominique Martin, Mohammed Ben Bari, Taı̈b Jei, Pierre Druilhe, Henri J. Vial
Journal: Blood (1998)
Protective Effect of the Double-Stranded Polyribonucleotide, Polyinosinic-Polycytidylic Acid, Against Rat Erythroblastosis Induced by Murine Erythroblastosis Virus 2
Authors: Dennis J. Slamon
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Protective Effect of the Double-Stranded Polyribonucleotide, Polyinosinic-Polycytidylic Acid, Against Rat Erythroblastosis Induced by Murine Erythroblastosis Virus Get access Dennis J. Slamon Dennis J. Slamon Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 51, Issue 3, September 1973, Pages 851–863, https://doi.org/10.1093/jnci/51.3.851 Published: 01 September 1973 Article history Received: 27 February 1973 Accepted: 11 May 1973 Published: 01 September 1973
Long-Term Comparison of Simultaneous Topography-Guided Photorefractive Keratectomy Followed by Corneal Cross-linking versus Corneal Cross-linking Alone
Authors: Georgios A. Kontadakis, Vardhaman P. Kankariya, Konstantinos Tsoulnaras, Aristofanis I. Pallikaris, Argyro Plaka, George D. Kymionis
Journal: Ophthalmology (2016)
SL 12 Murine T -Lymphoma: A New Model for Tumor Cell Heterogeneity&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: C L MacLeod, S E Weinroth, C Streifinger, S M Glaser, E F Hays
Journal: JNCI Journal of the National Cancer Institute (1985)

It has been observed that subclones from the spontaneous murine AKR/J T-Iymphoma cell line SL12 with similar in vitro growth characteristics exhibit stable differences in tumorigenicity. The cell line is composed of at least three distinct cloned cell types that are highly, moderately, or poorly tumorigenic in syngeneic host animals. When healthy, young, syngeneic host animals were given iv injections with the same number of viable growth phase cells, each cloned cell type had a different tumor incidence, latent period, and pattern of tumor spread. The unusual stability of the cloned cell lines is shown by a similar incidence, latency, and spread of the tumors when studied after more than 1 year of continuous in vitro culture. The SL 12 clones also differ in several phenotypic characteristics commonly used to classify thymocyte maturation, e.g., a) the expression of three of seven surface antigens examined, b) the cellular response to glucocorticoid hormone, and c) the expression of terminal deoxynucleotidyl transferase.
Feasibility of pegfilgrastim as haematopoietic support for dose-dense every-2-week adjuvant chemotherapy in breast cancer
Authors: P. Gomez, E. Vilar, C. Saura, J. Cortes, A. Ocaña, M. Bellet, J. Carrera, J. Baselga
Journal: Journal of Clinical Oncology (2006)

18606 Background: Dose-dense sequential chemotherapy has been safety supported with Filgrastim (F). Pegfilgrastim (PEGF) is a pegylated recombinant human granulocyte colony-stimulating factor (G-CSF) that has a long half-life, a fact that facilitates a less frequent dosing. Its safety and efficacy has been established in 21- and 28-days schedules. Methods: We have performed a retrospective analysis of medical records of 2 cohort of patients (n=38) treated at our institution between December 2003 and November 2005. All patients received Adriamicin 60 mg/m 2 plus Ciclophosphamide 600 mg/m 2 q2w for 4 cycles followed by Paclitaxel 175 mg/m 2 q2w for 4 cycles. As G-CSF support, in Cohort A (n=29) PEGF was administered 6 mg on day 2 of each cycle and in Cohort B (n=9) F days 3 to 10 at 5 μg/kg. The primary end point was to explore the feasibility and safety in terms of febrile neutropenia (FN) events, number of treatment delays (TD), incidence of neutropenia grade 3 (NPG3) and 4 (NPG4) and mean absolute neutrophil count (ANC) on day 14 of cycle 1 to 7 for both groups. Indirect comparisons have been performed. Results: Patients characteristics in both cohorts were well balanced, except for age in cohort A compared with cohort B (44,89 versus 52,5, p = 0,02). FN events and TD were increased in cohort B compared with cohort A (22% versus 0%, p=0.051, both comparisons). No statistically significant difference in number of episodes of NPG3 and NPG4 was observed. Median ANC on day 14 for each treatment cycle was significantly greater for Cohort A than Cohort B, except for cycle 6. Conclusions: PEGF is very safe and efficacy in patients treated with dose-dense sequential adjuvant chemotherapy for breast cancer. It could be even more efficient than F in preventing febrile neutropenia events. [Table: see text]
A comprehensive evaluation of the prognostic value of ERCC1 protein expression, mRNA and genotype in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN)
Authors: D. Hao, H. Y. Lau, M. Eliasziw, A. Box, R. Diaz, B. Shin, S. P. Lees-Miller, A. M. Magliocco
Journal: Journal of Clinical Oncology (2008)

6011 Background: ERCC1 has been associated with resistance to cisplatin (CDDP). In this retrospective study we analyzed ERCC1 protein expression, mRNA levels and single nucleotide polymorphisms (SNP) at codon 118 and examined each as a potential predictive/prognostic marker in LA-SCCHN pts treated with concurrent CDDP and radiation (CCRT). Methods: Records of 91 consecutive LA-SCCHN pts treated at the Tom Baker Cancer Centre between Aug 2000 and Mar 2005 were reviewed. ERCC1 was evaluated from pre-treatment formalin-fixed paraffin-embedded (FFPE) biopsies. Protein expression was assessed by conventional immunohistochemistry (IHC) using a 4-point semiquantitative scale as well as by immunofluorescence combined with automated quantitative analysis (AQUA). Quantitative RT-PCR and a pre-made TAQMAN genotyping assay were used to evaluate mRNA levels and the codon 118 SNP respectively. Results: FFPE biopsies were available from 57 pts (63%). Patient characteristics were as follows: mean age 56.4 years (range 43–75), 82.5% male, 77.2% KPS > 80%, 50.9% oropharyngeal primaries. ERCC1 protein expression was high in 39 pts (72%) by IHC versus 17 pts (31%) using AQUA. Ten pts (26%) had high levels of mRNA. C/C, C/T and T/T genotype frequencies were 17%, 43%, and 40%, respectively. ERCC1 IHC grading was significantly Spearman correlated (r=0.47) with AQUA scores. mRNA and protein expression were not correlated. The complete response rate was 89.3%. With a median follow-up of 44 months (range 3, 85), the 5 year overall survival (OS) was 68.2%. ERCC1 levels did not predict response, regardless if the pts received 100% versus <100% of CDDP. A nonsignificant increase in locoregional recurrence (LRR), recurrence at any site (ALLREC) and worse OS was observed with high IHC score. The C/C and C/T genotype was also predictive of LRR (HR=7.4, 95%CI: 0.9–58.6, p=0.06), ALLREC (HR=8.6, 95%CI: 1.1–67.2, p=0.04), and higher mortality (HR=3.9, 95%CI: 0.8–17.8, p=0.08). mRNA levels did not predict outcome. Conclusions: Our preliminary results suggest that high ERCC1 protein expression as well as the C/C or C/T genotype may be potential prognostic markers for LA-SCCHN pts treated with CCRT. No significant financial relationships to disclose.
Capecitabine and docetaxel in advanced gastric adenocarcinoma, an ongoing phase II study
Authors: P. C. Thuss-Patience, A. Kretzschmar, A. Loew, G. Massenkeil, D. Pink, B. Lebedinzew, S. Micheel, B. Dörken, P. Reichardt
Journal: Journal of Clinical Oncology (2005)

4224 Background: Docetaxel shows promising activity as single agent and in chemotherapy combination regimens against gastric cancer. In a randomized phase II study it has been shown that a dual combination of docetaxel and continuous infusion 5-FU compared to the reference arm Epirubicin, Cisplatin and 5-FU (ECF) is a well tolerated and very active regimen (Thuss-Patience et al. JCO 2005). In this study we replace the 5-FU infusion with oral fluoropyrimidines and evaluate the efficacy of the dual combination docetaxel and capecitabine (CapDoc). Here we report a preliminary analysis of this ongoing prospective multicenter phase II trial. Methods: Eligibility: Metastatic or locally advanced gastro-esophageal-junction or gastric adenocarcinoma, ECOG PS 0–2, no prior palliative chemotherapy. Chemotherapy: Docetaxel 75 mg/m2 d1, Capecitabine 2000 mg/m2 d1–14, q3w. Results: 17 patients (pts) are included in this ongoing trial. Age: 32–79 yrs (median 60), M/F 4/13, ECOG PS 0: 4 pts, 1: 11 pts, 2: 2 pts. Number of organs involved by metastases: 1: 2 pts, 2: 6 pts, 3: 5 pts, 4: 3pts, 5: 1 pt. Measurable disease (RECIST): 17 pts. 59 cycles of chemotherapy are administered so far. Toxicity: 13 pts are evaluable for toxicity (worst grade per patient/% of pts): Grade 1/2/3/4: Nausea: 38%/8%/-/-/, vomiting: 8%/23%/-/-/, diarrhea: 23%/23%/-/-/, asthenia: 38%/31%/-/-/, stomatitis: 8%/15%/ 8%/-/, alopecia: 62%/23%/-/-/, fever not neutropenic: 8%/23%/-/-/, neutropenic fever: -/-/8%/-/, nail changes: 15%/15%/-/-/, atrial fibrillation: -/-/15%/-/, paresthesia: 15%/8%/-/-/, dizziness: 15%/8%/15%/-/, hand-foot-syndrome: 15%/8%/23%/-/, leuko-neutropenia: -/-/23%/31%, thrombocytopenia: 8%/-/-/-/, anemia: 8%/8%/8%/-/, fluid retention: 23%/-/-/-/, pulmonary embolism: -/8%/-/8%. Response: 11 pts are so far evaluable for response: CR 1 pt, PR 5 pts, NC 5 pts, PD 0 pts, (objective response rate: 55%). So far no patient showed primary resistance to CapDoc. Conclusion: These preliminary data suggest that CapDoc is a well tolerated combination with very promising efficacy in gastric cancer. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Roche, Aventis Roche, Aventis
Substitution of Val for Met at residue 239 of platelet glycoprotein Ib alpha in Japanese patients with platelet-type von Willebrand disease
Authors: H Takahashi, M Murata, T Moriki, H Anbo, T Furukawa, K Nikkuni, A Shibata, M Handa, Y Kawai, K Watanabe
Journal: Blood (1995)
A protease inhibitor from the tick rhipicephalus boophilus microplus attenuated parenchymal destruction in elastase-induced emphysema
Authors: Clarice Rosa Olivo, Juliana Dias Lourenço, Francine M. Almeida, Luana Paiva Neves, Petra Mello Arantes, Carla Máximo Prado, Iolanda Tibério, Aparecida S. Tanaka, Sérgio D. Sasaki, Milton Arruda Martins, Fernanda Dtqs Lopes
Journal: European Respiratory Journal (2013)

We showed previously that a protease inhibitor (BMTIA) instillation, 1h after the emphysema induction, attenuated parenchymal destruction. To evaluate if BMTIA could attenuate parenchymal destruction even after the emphysema development.40 adults C57BL/6 mice were submitted to either a nasal drop of 50 µl of porcine pancreatic elastase (PPE) or saline (S) and 21 days after, animals received 2 doses with 7 days intervals of either BmTIA or vehicle (VE) by nasal instillation. In the end of the BMTIA treatment, animals were anesthetized to evaluate lung function. Airway resistance (RAW), tissue damping (Gtis) and tissue elastance (Htis) were measured using Flexivent small animal ventilator. After sacrifice, lungs were fixed and paraffin embedded for measurements of mean linear intercept (Lm), number of macrophages and MMP-12 positive cells in parenchyma.We observed a significant decrease in Htis values in PPE compared to VE groups. Lm values were increased in PPE groups, whereas the PPE-BmTIA showed a significant decrease in Lm compared to PPE-VE. Compared to VE groups, the number of macrophages and MMP-12 positive cells in parenchyma were increased in PPE groups, whereas the BMTIA treatment reduced MMP-12 positive cells in PPE-BMTIA compared to PPE-VE. There was no significant difference between the groups when we compared Gtis and Raw values.Although treatment with BMTIA has not improved lung function and macrophages infiltration in parenchyma, it reduced the Lm values and the number of MMP-12 positive cells even after the emphysema development, probably due to attenuation in protease-antiprotease imbalance.Supported by FAPESP, LIMHC-FMUSP, Brazil.